By Brad Sorensen, CFA NASDAQ: ENSC READ THE FULL ENSC RESEARCH REPORT Ensysce Biosciences (NASDAQ: ENSC) is a clinical stage company that is developing novel opioids that provide the needed pain ...

Fourth Quarter Highlighted by Clinical and Regulatory Milestones Positioning PF614 for Late-Stage Advancement ~ SAN DIEGO, CA / ACCESS Newswire / March 30, 2026 / Ensysce Biosciences, Inc.

Ensysce Biosciences shares are trading lower by 30% during Thursday's session. The company announced a $5 million registered direct offering and concurrent private placement. Post-Labor Day Trading ...

Ensysce Biosciences, Inc. (ENSC) stock price is 0.55 and Ensysce Biosciences, Inc. (ENSC) 10-day simple moving average is 0.49. Ensysce Biosciences, Inc. (ENSC) stock price is 0.55 and Ensysce ...

Detailed price information for Ensysce Biosciences Inc (ENSC-Q) from The Globe and Mail including charting and trades.

Fintel reports that on September 25, 2023, HC Wainwright & Co. maintained coverage of Ensysce Biosciences (NASDAQ:ENSC) with a Buy recommendation. As of August 31, 2023, the average one-year price ...

Short interest in Ensysce Biosciences Inc (NASDAQ:ENSC) increased during the last reporting period, rising from 144.54K to 344.43K. This put 14.69% of the company's publicly available shares short.